GammaCan International to Webcast Presentation at the 3rd Annual Rodman & Renshaw Global Healthcare Conference
10 May 2006 - 9:30PM
Business Wire
GammaCan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
Patrick Schnegelsberg, Chief Executive Officer, will provide a
company overview at the Rodman & Renshaw 3rd Annual Global
Healthcare Conference on Tuesday, May 16 at 8:40 am CEST in Monte
Carlo, Monaco. Patrick Schnegelsberg, GammaCan International's
recently appointed CEO will provide an update on the Company's
pipeline to treat cancer and introduce VitiGam, GammaCan's lead
program to treat malignant melanoma. To access the live webcast,
please go to www.GammaCan.com and click on the "Investor Relations"
link. The replay will be available for approximately one week
following the presentation. About VitiGam: VitiGam is a second
generation IVIg product and a first-in-class anti-cancer
immunotherapy. GammaCan plans on having VitiGam to enter phase I/II
testing under a US IND in the near future and the Company recently
held a pre-IND meeting with the FDA. VitiGam is being designed to
target metastatic melanoma patients with Stage 3 and 4 melanoma.
VitiGam is an IVIg product that is different from standard IVIg: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IVIg (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IVIg in general. About
GammaCan: GammaCan is focusing on the commercialization of an
innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IVIg, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IVIg works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IVIg derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IVIg and vitiligo-derived IVIg (VitiGam). For more information
about GammaCan visit www.GammaCan.com or call the company's
headquarters in Givat Shmuel, Israel at 972 3 5774475 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding: the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IVIg into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, inability to hire
appropriate staff to develop the technology, unforeseen technical
difficulties in developing the technology, inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early stage medical research
and development companies filed with the SEC on EDGAR.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024